One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
-
Patent number: 9662399Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.Type: GrantFiled: March 27, 2015Date of Patent: May 30, 2017Assignee: Purdue Pharma L.P.Inventors: Debora Guido, Haiyong Hugh Huang
-
Patent number: 9662390Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.Type: GrantFiled: March 7, 2006Date of Patent: May 30, 2017Assignee: THE UNIVERSITY OF CHICAGOInventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia
-
Patent number: 9655855Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.Type: GrantFiled: September 17, 2014Date of Patent: May 23, 2017Assignee: Purdue Pharma L.P.Inventors: Bianca Brögmann, Silke Mühlau, Christof Spitzley
-
Patent number: 9657027Abstract: Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.Type: GrantFiled: January 22, 2016Date of Patent: May 23, 2017Assignee: Johnson Matthey Public Limited CompanyInventors: Saroop Singh Matharu, Ewart Grant, Brian W. Heinrich
-
Patent number: 9657028Abstract: Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.Type: GrantFiled: January 22, 2016Date of Patent: May 23, 2017Assignee: Johnson Matthey Public Limited CompanyInventors: Saroop Singh Matharu, Ewart Grant, Brian W. Heinrich
-
Patent number: 9642849Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.Type: GrantFiled: April 7, 2016Date of Patent: May 9, 2017Assignee: H. LUNDBECK A/SInventors: Lars Torup, Afsaneh Abbariki, Anna Bladström, Christine Persson, Didier Meulien, Per Sørensen, Thomas Jon Jensen, Jette Buch Østergaard
-
Patent number: 9642801Abstract: The present invention provides a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy and or reduce the side effects of tapentadol. The present invention further provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy and or reduce the side effects of tapentadol.Type: GrantFiled: April 21, 2011Date of Patent: May 9, 2017Assignee: Gruenenthal GmbHInventor: Ramesh Sesha
-
Patent number: 9629837Abstract: The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subject's body faster than it is being absorbed.Type: GrantFiled: March 17, 2015Date of Patent: April 25, 2017Assignee: MALLINCKRODT LLCInventors: Krishna Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
-
Patent number: 9597327Abstract: This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.Type: GrantFiled: June 22, 2015Date of Patent: March 21, 2017Assignee: Progenics Pharmaceuticals, Inc.Inventors: Harold D. Doshan, Julio Perez
-
Patent number: 9597403Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.Type: GrantFiled: March 17, 2014Date of Patent: March 21, 2017Assignee: KEMPHARM, INC.Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
-
Patent number: 9549924Abstract: The present invention provides method and compositions for the treatment of peripheral neuropathic pain by administering to a patient a therapeutically effective amount of a buprenorphine dimer compound, wherein the two buprenorphine portions are linked via an ethylene spacer, and wherein the spacer is bonded to the two opioid molecules via an ether bond. Preferably, the active agent is provided in the form of an injectable depot.Type: GrantFiled: October 26, 2015Date of Patent: January 24, 2017Assignee: ORPHOMED, INC.Inventor: Nikhilesh Nihala Singh
-
Patent number: 9517208Abstract: Abuse-deterrent dosage forms (e.g., orally administered dosage forms, transdermal dosage forms, suppositories, etc.), processes for formulating pharmaceutical dosage forms comprising an active agent susceptible to abuse (e.g., an opioid agonist, a benzodiazepine, a stimulant) such that the resulting dosage forms are abuse-deterrent are described. Also described are methods of deterring abuse of pharmaceutical dosage forms.Type: GrantFiled: March 13, 2014Date of Patent: December 13, 2016Assignee: Purdue Pharma L.P.Inventors: Debora L Guido, Haiyong Huang
-
Patent number: 9498511Abstract: The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.Type: GrantFiled: July 3, 2014Date of Patent: November 22, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Jau-Shyong Hong, Liya Qin, Guorong Li, Michelle Block, Wei Zhang, Po-See Chen, Giia-Shuen Peng
-
Patent number: 9498474Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .Type: GrantFiled: July 29, 2014Date of Patent: November 22, 2016Assignee: Alkermes Pharma Ireland LimitedInventors: Daniel Deaver, Elliot Ehrich
-
Patent number: 9498444Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.Type: GrantFiled: July 1, 2015Date of Patent: November 22, 2016Assignee: LOCL PHARMA, INC.Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
-
Patent number: 9492445Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.Type: GrantFiled: September 30, 2015Date of Patent: November 15, 2016Assignee: Wyeth, LLCInventors: Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
-
Patent number: 9487531Abstract: The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient.Type: GrantFiled: April 16, 2014Date of Patent: November 8, 2016Assignee: BioPharma Works LLCInventors: Robert Volkmann, Anthony Marfat, Peter Cornelius, Panayiotis Zagouras, Frederick Raymond Nelson, Anton Franz Joseph Fliri
-
Patent number: 9474749Abstract: Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided.Type: GrantFiled: August 15, 2014Date of Patent: October 25, 2016Assignee: The Research Foundation for the State University of New YorkInventors: George B. Stefano, Patrick Cadet, Kirk J. Mantione, Wei Zhu
-
Patent number: 9468611Abstract: The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the NMDA receptor and NE receptor of the subject.Type: GrantFiled: March 14, 2013Date of Patent: October 18, 2016Assignee: Relmada Therapeutics, Inc.Inventors: Paolo L. Manfredi, Charles E. Inturrisi
-
Patent number: 9468636Abstract: The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.Type: GrantFiled: February 20, 2015Date of Patent: October 18, 2016Assignee: MALLINCKRODT LLCInventors: Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
-
Patent number: 9458166Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.Type: GrantFiled: December 4, 2015Date of Patent: October 4, 2016Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
-
Patent number: 9440986Abstract: Crystalline, anhydrous hydrochloride salts of 4,5?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt and such a salt as a medicament and for the treatment and/or prevention of pain.Type: GrantFiled: February 4, 2015Date of Patent: September 13, 2016Assignee: ENDO PHARMACEUTICALS INC.Inventors: Andreas Fischer, Dagmar Peters-Groth, Dagmar Lischke
-
Patent number: 9422302Abstract: An opioid narcotics used for the treatment of moderate-to-severe pain that primarily exert their analgesic effects through ? receptors. Although, traditional ? agonists can cause undesired side effects, including tolerance, addition of ? antagonists can attenuate said side effects. The present invention includes 4a,9-dihydroxy-7a-(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one (UMB 425) a 5,14-bridged morphinan-based orvinol precursor, along with analogs of morphine, dihydromorphine, hydromorphone, codeine, dihydrocodeine, hydrocodone and ethylmorphine. Although UMB 425 lacks ?-specific motifs, conformationally sampled pharmacophore models for ? and ? receptors predict it to have efficacy similar to morphine at ? receptors and similar to naltrexone at ? receptors, due to the compound sampling conformations in which the hydroxyl moiety interacts with the receptors similar to orvinols.Type: GrantFiled: March 6, 2014Date of Patent: August 23, 2016Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Andrew Coop, Alexander D. Mackerell, Rae Matsumoto
-
Patent number: 9415034Abstract: A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, ?-naphthoflavone, ?-naphthoflavone, hesperetin, terpineol, (+)-limonene, ?-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof.Type: GrantFiled: November 28, 2008Date of Patent: August 16, 2016Assignee: NATIONAL DEFENSE MEDICAL CENTERInventors: Yoa-Pu Hu Oliver, Cheng-Huei Hsiong, Mei-Ting Wang, Li-Heng Pao
-
Patent number: 9415045Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:Type: GrantFiled: January 16, 2015Date of Patent: August 16, 2016Assignee: Alkermes, Inc.Inventors: Laura Cook Blumberg, Derrick Arnelle
-
Patent number: 9402813Abstract: Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.Type: GrantFiled: June 24, 2015Date of Patent: August 2, 2016Assignee: LOCL PHARMA, INC.Inventor: Paul Bosse
-
Patent number: 9403838Abstract: The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael acceptor precursors.Type: GrantFiled: December 30, 2014Date of Patent: August 2, 2016Assignee: Controlled Chemicals, Inc.Inventors: Jules A. Shafer, Vladislav V. Telyatnikov, Hao Wang
-
Patent number: 9399022Abstract: Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.Type: GrantFiled: June 24, 2015Date of Patent: July 26, 2016Assignee: LOCL PHARMA, INC.Inventor: Paul Bosse
-
Patent number: 9393241Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.Type: GrantFiled: February 24, 2014Date of Patent: July 19, 2016Assignee: PHARNEXTInventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
-
Patent number: 9388112Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.Type: GrantFiled: January 6, 2011Date of Patent: July 12, 2016Assignees: The University of British Columbia, Brittish Columbia Cancer Agency BranchInventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
-
Patent number: 9321780Abstract: The present invention provides a buprenorphine dimer compound, wherein the two buprenorphine portions are linked via an ethylene spacer, wherein the spacer is bonded to the two opioid molecules via an ether bond. Pharmaceutical compositions comprising such a buprenorphine dimer drug are also disclosed, and the use of such compounds in the treatment of gastrointestinal hyperalgesia generally and in particular diarrhea-predominant irritable bowel syndrome.Type: GrantFiled: April 27, 2015Date of Patent: April 26, 2016Assignee: OrphoMed, Inc.Inventor: Nikhilesh Nihala Singh
-
Patent number: 9289583Abstract: Systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject using a device are disclosed. The dispensing device includes a lock-out feature and a means to retard or prevent saliva and/or moisture ingress such that the drug dosage forms in the device remain dry prior to administration.Type: GrantFiled: October 30, 2007Date of Patent: March 22, 2016Assignee: AcelRx Pharmaceuticals, Inc.Inventors: Pamela Palmer, Andrew I Poutiatine, Charles Rampersaud, Bruce Edwards, Edmond Chiu, Thomas Schreck, Stelios Tzannis, Larry Hamel
-
Patent number: 9283220Abstract: Provided are compositions comprising opioid antagonists, such as naltrexone naloxone, or nalmefene, or their pharmaceutically acceptable salts, and methods for treating conditions caused by the varicella-zoster virus therewith.Type: GrantFiled: March 31, 2011Date of Patent: March 15, 2016Assignee: IMUNEKS FARMA ILAC SANAYI VE TICARET ANONIM SIRKETI PAK IS MERKEZIInventors: Ibrahim Mustafa Iskender Pisak, Semra Bingol, Mehmet Levent Selamoglu, Mehmet Pisak
-
Patent number: 9273060Abstract: Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.Type: GrantFiled: March 5, 2014Date of Patent: March 1, 2016Assignee: Johnson Matthey Public Limited CompanyInventors: Saroop Singh Matharu, Ewart Grant, Brian W. Heinrich
-
Patent number: 9226907Abstract: The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily. Preferably, the dosage form is about 30 mg of hydrocodone and about 1000 mg of acetaminophen taken twice daily. Alternatively, the dosage form is about 15 mg of hydrocodone and about 500 mg of acetaminophen taken twice daily.Type: GrantFiled: February 4, 2009Date of Patent: January 5, 2016Assignee: AbbVie Inc.Inventors: Rita I. Jain, Andrea E. Best, Earle Lockhart, Steven E. Marx, James W. Thomas, Pamela Giang Vo
-
Patent number: 9211293Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:Type: GrantFiled: December 17, 2012Date of Patent: December 15, 2015Assignee: Alkermes Pharma Ireland LimitedInventors: Daniel Deaver, Elliot Ehrich
-
Patent number: 9205081Abstract: Disclosed are compositions for treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4) and the second compound is a cyclooxygenase (COX) inhibitor that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone. Examples of cyclooxygenase inhibitors include ibuprofen, naproxen, meloxicam, diclofenac and meclofenamic acid, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic pain and nociceptive pain with an allodynic component.Type: GrantFiled: March 15, 2013Date of Patent: December 8, 2015Assignee: Allodynic Therapeutics, LLCInventor: Annette Channa Toledano
-
Patent number: 9205082Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: GrantFiled: March 14, 2014Date of Patent: December 8, 2015Assignee: Purdue Pharma L.P.Inventors: Robert F. Kaiko, Robert D. Colucci
-
Patent number: 9193739Abstract: In this application is described a composition and method for inducing in a subject anti-hapten antibodies without inducing antibodies to the carrier protein. Kits for designing and making compositions with desired haptens are also described.Type: GrantFiled: February 8, 2013Date of Patent: November 24, 2015Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH HUMAN SERVICESInventors: Carl R. Alving, Gary R. Matyas, Arthur E. Jacobson, Fuying Li, Malliga R. Iyer, Kenner C. Rice, Kejun Cheng, Alexander Mayorov
-
Patent number: 9180125Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.Type: GrantFiled: July 2, 2014Date of Patent: November 10, 2015Assignee: Wyeth, LLCInventors: Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
-
Patent number: 9155734Abstract: The present invention relates generally to a sterile hydromorphone hydrochloride solution that is substantially free of buffer.Type: GrantFiled: March 6, 2013Date of Patent: October 13, 2015Assignee: Mallinckrodt LLCInventors: John J. Foster, Thomas R. Prentice
-
Patent number: 9156821Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: GrantFiled: October 31, 2014Date of Patent: October 13, 2015Assignee: RENSSELAER POLYTECHNIC INSTITUTEInventor: Mark P. Wentland
-
Patent number: 9145420Abstract: The present disclosure is directed to crystalline forms of morphine sulfate and pharmaceutical compositions comprising any of the crystalline forms of morphine sulfate. Also provided are processes for the preparation of crystalline forms of morphine sulfate.Type: GrantFiled: March 27, 2015Date of Patent: September 29, 2015Assignee: Johnson Matthey Public Limited CompanyInventors: Nicholas D. Paschalides, Mahmoud Mirmehrabi
-
Patent number: 9125947Abstract: The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: GrantFiled: September 23, 2014Date of Patent: September 8, 2015Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle
-
Patent number: 9125898Abstract: The present invention provides a method of treatment, prevention and/or delay of progression of neuropathic pain by a specific dosing regime of acetam derivatives.Type: GrantFiled: September 24, 2009Date of Patent: September 8, 2015Assignee: NEUROTUNE AGInventors: Carlo Farina, Carla Ghelardini, Ruggero Fariello
-
Patent number: 9119848Abstract: The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:Type: GrantFiled: October 13, 2010Date of Patent: September 1, 2015Assignee: Alkermes Pharma Ireland LimitedInventors: Bernard Silverman, Fen-Ni Fu, Chengyun Guo
-
Patent number: 9107954Abstract: Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the ?-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS.Type: GrantFiled: December 12, 2014Date of Patent: August 18, 2015Assignee: Virginia Commonwealth UniversityInventors: Yan Zhang, Kurt F. Hauser, Dana E. Selley
-
Patent number: 9101625Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.Type: GrantFiled: August 29, 2007Date of Patent: August 11, 2015Assignee: PURDUE PHARMA L.P.Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
-
Patent number: 9084817Abstract: A chemically stable oral preparation with an excellent dissolution property comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof is disclosed. The oral preparation according to the present invention comprises a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof as an effective ingredient and an organic acid, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C. The method for improving dissolution property and chemical stability of an oral preparation according to the present invention comprises incorporating an organic acid in the oral preparation comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C.Type: GrantFiled: May 20, 2008Date of Patent: July 21, 2015Assignee: TORAY INDUSTRIES, INC.Inventors: Kotoe Ohta, Satoshi Minakami, Hiroyuki Tokumitsu
-
Patent number: 9073933Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: February 6, 2012Date of Patent: July 7, 2015Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes TechnologiesInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper